Tharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization

Company Overview - Tharimmune, Inc. (THAR) is a pre-revenue biotech research and development firm with no long-term debt [1] - The company reported annual expenses of $10.3 million and $7.6 million in unspecified revenue [1] Investment Strategy - The investment approach focuses on a diversified portfolio including low-cost index funds, U.S. T-Bills/Treasuries, investment real estate, and a small percentage of individual stocks [1] - Individual stocks are selected for long-term growth potential or to provide higher income compared to real estate investments [1] Current Holdings - Current individual stock holdings include AMZN, TSMC, EPD, TROW, and BMNR, with a long position in all except TROW, where covered calls are consistently sold [1] Analyst's Position - The analyst holds a beneficial long position in THAR through stock ownership, options, or other derivatives [1] - The article reflects the analyst's personal opinions and is not compensated beyond contributions to Seeking Alpha [1]